MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jbc.2021.100928

Медицинская библиотека · The Journal of biological chemistry · 2021

GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice.

Pearce Andrew C, Bamford Mark J, Barber Ruth, Bridges Angela, Convery Maire A, Demetriou Constantinos, Evans Sian, Gobbetti Thomas, Hirst David J, Holmes Duncan S, Hutchinson Jonathan P, Jayne Sandrine, Lezina Larissa, McCabe Michael T, Messenger Cassie, Morley Joanne, Musso Melissa C, Scott-Stevens Paul, Manso Ana Sousa, Schofield Jennifer, Slocombe Tom, Somers Don, Walker Ann L, Wyce Anastasia, Zhang Xi-Ping, Wagner Simon D

СтатьяПеревод в очереди

Аннотация

B-cell lymphoma 6 (BCL6) is a zinc finger transcriptional repressor possessing a BTB-POZ (BR-C, ttk, and bab for BTB; pox virus and zinc finger for POZ) domain, which is required for homodimerization and association with corepressors. BCL6 has multiple roles in normal immunity, autoimmunity, and some types of lymphoma. Mice bearing disrupted BCL6 loci demonstrate suppressed high-affinity antibody responses to T-dependent antigens. The corepressor binding groove in the BTB-POZ domain is a potential target for small compound-mediated therapy. Several inhibitors targeting this binding groove have been described, but these compounds have limited or absent in vivo activity. Biophysical studies of a novel compound, GSK137, showed an in vitro pIC50 of 8 and a cellular pIC50 of 7.3 for blocking binding of a peptide derived from the corepressor silencing mediator for retinoid or thyroid hormone receptors to the BCL6 BTB-POZ domain. The compound has good solubility (128 μg/ml) and permeability (86 nM/s). GSK137 caused little change in cell viability or proliferation in four BCL6-expressing B-cell lymphoma lines, although there was modest dose-dependent accumulation of G1 phase cells. Pharmacokinetic studies in mice showed a profile compatible with achieving good levels of target engagement. GSK137, administered orally, suppressed immunoglobulin G responses and reduced numbers of germinal centers and germinal center B cells following immunization of mice with the hapten trinitrophenol. Overall, we report a novel small-molecule BCL6 inhibitor with in vivo activity that inhibits the T-dependent antigen immune response.

Для цитирования: Pearce Andrew C, Bamford Mark J, Barber Ruth, Bridges Angela, Convery Maire A, Demetriou Constantinos, Evans Sian, Gobbetti Thomas, Hirst David J, Holmes Duncan S, Hutchinson Jonathan P, Jayne Sandrine, Lezina Larissa, McCabe Michael T, Messenger Cassie, Morley Joanne, Musso Melissa C, Scott-Stevens Paul, Manso Ana Sousa, Schofield Jennifer, Slocombe Tom, Somers Don, Walker Ann L, Wyce Anastasia, Zhang Xi-Ping, Wagner Simon D. GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice.. The Journal of biological chemistry. 2021. DOI: 10.1016/j.jbc.2021.100928.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.